Publications

JITC: Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
Brignole, Calarco, Bensa, Giusto, Perri, Ciampi, Corrias, Astigiano, Cilli, Loo, Bonvini, Pastorino, Ponzoni; J Immunother Cancer: first published as 10.1136/jitc-2023-007174 on 28 September 2023

AACR 2022 - Targeting B7-H3 in Prostate Cancer: Preclinical Proof-of-Concept with MGC018, an Investigational Anti-B7-H3 Antibody-drug Conjugate
Juniper A. Scribner, Francine Z. Chen, Anushka De Costa, Ying Li, Michael Chiechi, Thomas Son, Jeff Hooley, Jonathan Li, Scott Koenig, Chet Bohac, Ezio Bonvini, Paul A. Moore, Deryk Loo

ESMO 2021 - MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion
Eugene Shenderov, Girish Mallesara, Piotr Wysocki, Wen Xu, Rodryg Ramlau, Andrew Weickhardt, Jakub Zolnierek, Alexander Spira, Anthony M. Joshua, John Powderly, Emmanuel S Antonarakis, Sekwon Jang, Jeanny Aragon-Ching, John Shen, Channing Paller, Nicholas Vogelzang, Kirsten Leu, Javier Cortés, Chet Bohac, Iwona Lugowska

ASCO 2021: Phase 1 Dose Escalation Study of MGC018, an anti-B7-H3 Antibody-Drug Conjugate (ADC), In Patients with Advanced Solid Tumors
Sekwon Jang, John Powderly, Alexander Spira, Iwona Lugowska, Girish Mallesera, Andrew Weickhardt6, Piotr Wysocki, Jakub Zolniereck, Ouiam Bakkacha, Deryk Loo, Chet Bohac, Jeanny Aragon-Ching, Eugene Shenderov, Emmanuel Antonarakis, Manish Sharma

MOLECULAR CANCER THERAPEUTICS - Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner, Jennifer G. Brown, Thomas Son, Michael Chiechi, Pam Li, Sharad Sharma, Hua Li, Anushka De Costa, Ying Li, Yan Chen, Ann Easton, Nicholas C. Yee-Toy, Francine Z. Chen, Sergey Gorlatov, Bhaswati Barat, Ling Huang, Christina R. Wolff, Jeff Hooley, Tim E. Hotaling, Timur Gaynutdinov, Valentina Ciccarone, James Tamura, Scott Koenig, Paul A. Moore, Ezio Bonvini, Deryk Loo; DOI: 10.1158/1535-7163.MCT-20-0116; Molecular Cancer Therapeutics, September 2020.

AACR 2020 - MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3, Exhibits Immunomodulatory Activity and Enhanced Antitumor Activity in Combination with Checkpoint Inhibitors
Juniper A. Scribner, Michael Chiechi, Pam Li, Thomas Son, Jeff Hooley, Ying Li, Anushka De Costa, Peter Lung, Nicholas Yee-Toy, Francine Chen, Zhuangyu Pan,  Bhaswati Barat, Christina Wolff, Valentina Ciccarone, James Tamura, Scott Koenig, Chet Bohac, Jon Wigginton, Paul A. Moore, Ezio Bonvini, Deryk Loo

ASCO 2020 - Preliminary Dose Escalation Results from a Phase 1/2, First-in-Human Study of MGC018 (Anti-B7-H3 Antibody-Drug Conjugate) in Patients with Advanced Solid Tumors
John Powderly, Sekwon Jang, Juniper Scribner, Deryk Loo, Chet Bohac, Alexander Spira, Manish Sharma

SITC 2018 - A Phase 1/2, First-in-Human, Dose Escalation Study of MGC018 (Anti-B7-H3 Antibody-Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors
John Powderly, Deryk Loo, Anthony Joshua, Johanna Bendell, Alexander Spira, Joanna Lohr, Pepi Pencheva, Jichao Sun, Jan Baughman, Ezio Bonvini, Jennifer Brown, Nehal Lakhani, Jon M Wigginton

AACR 2017 - Preclinical Development of a Duocarmycin-based Antibody-Drug Conjugate Targeting B7-H3 for Solid Cancer
Thomas Son, Juniper A. Scribner, Jeff Hooley, Michael Chiechi, Pam Li, Tim E. Hotaling, Anushka De Costa, Yan Chen, Francine Chen, Bhaswati Barat, Ling Huang, Valentina Ciccarone, Timur Gaynutdinov, James Tamura, Scott Koenig, Syd Johnson, Paul A. Moore, Ezio Bonvini, Deryk Loo

AACR 2016 - Anti-B7-H3 Antibody-Drug Conjugates as Potential Therapeutics for Solid Cancer
Deryk Loo, Juniper Scribner, Thomas Son, Jeff Hooley, Tim Hotaling, Michael Chiechi, Pam Li, Anushka De Costa, Yan Chen, Ann Easton, Francine Chen, Bhaswati Barat, Valentina Ciccarone, James Tamura, Mark Kubik, Scott Koenig, Syd Johnson, Paul A. Moore, and Ezio Bonvini

CELL REPORTS MEDICINE 2020 - Development and Preliminary Clinical Activity of PD- 1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J. Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, Anushka De Costa, Sanjeev Kaul, Johanna Bendell, Gregory M. Cote, Jason J. Luke, Rachel E. Sanborn, Manish R. Sharma, Francine Chen, Hua Li, Gundo Diedrich, Ezio Bonvini, Paul A. Moore

ESMO 2020 - A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD019, an Investigational Bispecific PD-1 × CTLA-4 DART® Molecule in Patients with Advanced Solid Tumors
Manish R. Sharma, Rachel E. Sanborn, Gregory M. Cote, Johanna Bendell, Sanjeev Kaul, Francine Chen, Alexey Berezhnoy, Paul A. Moore, Ezio Bonvini, Bradley J. Sumrow, Jason J. Luke

Keystone 2019 - MGD019, a PD-1 x CTLA-4 Bispecific DART® Molecule, Provides Simultaneous Blockade of PD-1 and CTLA-4 Checkpoint Pathways
Alexey Berezhnoy, Kurt Stahl, Kalpana Shah, Tim Gaynutdinov, Daorong Liu, Ross La Motte-Mohs R, Jessica Saul, Jonathan Li, Douglas Smith, Jill Rillema, Sergey Gorlatov, Valentina Ciccarone, Ralph Alderson, Hua Li, James Tamura, Jennifer Brown, Bradley Sumrow, Jon Wigginton, Ezio Bonvini, Syd Johnson, Paul A. Moore

MGD019, a PD-1 x CTLA-4 Tetravalent Bispecific DART® Protein, Provides Optimal Dual Checkpoint Blockade
Alexey Berezhnoy, Kurt Stahl, Kalpana Shah, Daorong Liu, Jessica Saul, Jonathan Li*, Douglas Smith, Jill Rillema, Sergey Gorlatov, Valentina Ciccarone,  Ralph Alderson, Hua Li, James Tamura, Jennifer Brown, Bradley Sumrow, Jon Wigginton, Ezio Bonvini, Gundo Diedrich, Paul A. Moore

NATURE MEDICINE - Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-arm, Phase 2 Trial
Eugene Shenderov, Angelo M. De Marzo, Tamara L. Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E. Allaf, Carolyn Chapman, Paul A. Moore, Francine Chen, Kristina Sorg, Andrew M. White, Sarah E. Church, Briana Hudson, Paul A. Fields, Shaohui Hu, Samuel R. Denmeade, Kenneth J. Pienta, Christian P. Pavlovich, Ashley E. Ross, Charles G. Drake, Drew M. Pardoll, Emmanuel S. Antonarakis

ASCO 2022 - Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives
Eugene Shenderov, Angelo M. De Marzo MD, PhD, Tamara L. Lotan MD, Hao Wang PhD, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E. Allaf, Carolyn Chapman, Paul Moore, Francine Chen, Kristina Sorg, Andrew M. White, Sarah E. Church, Briana Hudson, Paul Fields, Shaohui Hu, Samuel R. Denmeade, Kenneth J. Pienta, Christian P. Pavlovich, Ashley E. Ross, Charles G. Drake, Drew Pardoll, Emmanuel S. Antonarakis

JOURNAL FOR IMMUNOTHERAPY OF CANCER - Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh Kalebasty, Victoria Atkinson, Alex A Adjei, Mahesh Seetharam, Ariel Birnbaum, Andrew Weickhardt, Vinod Ganju, Anthony M Joshua, Rosetta Cavallo, Linda Peng, Xiaoyu Zhang, Sanjeev Kaul, Jan Baughman, Ezio Bonvini, Paul A Moore, Stacie M Goldberg, Fernanda I Arnaldez, Robert L Ferris, Nehal J Lakhani. Journal for ImmunoTherapy of Cancer 2022;10:e004424. doi:10.1136/jitc-2021-004424

SITC 2018 - A Phase 1, Open-Label, Dose Escalation Study of Enoblituzumab in Combination with Pembrolizumab in Patients with Select Solid Tumors
Charu Aggarwal, Anthony Joshua, Robert Ferris, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B. Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan Zandberg, Arash Kalebasty, Victoria Atkinson,  Alex Adjei, Mahesh Seetharam, Ariel Birnbaum, Andrew Weickhardt, Vinod Ganju, Riva Bondarenko, Linda Peng, Tony Wu, Scott Currence, Jan Baughman, Ezio Bonvini, Stacie Goldberg, Jon Wigginton, Nehal Lakhani

SITC 2018 - Phase II Neoadjuvant and Immunologic Study of B7-H3 Targeting with Enoblituzumab in Localized Intermediate- and High-Risk Prostate Cancer
Eugene Shenderov, Karim Boudadi, Angelo DeMarzo, Mohamad E Allaf, Onur Ertunc, Igor Vidal, Carolyn Chapman, Hao Wang, Jim Vasselli, Jon Wigginton, Jan Davidson, Rehab Abdallah, Tanya O’Neal, Christian Pavlovich, Trinity Bivalacqua, Ashley E. Ross, Charles G. Drake, Drew Pardoll1 & Emmanuel S. Antonarakis

CLINICAL CANCER RESEARCH - Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton A, Li J, Rillema J, Licea M, Fieger C, Liang T, Mather J, Koenig S, Stewart S, Johnson S, Bonvini E, Moore P. Clinical Cancer Research 2012; doi:10.1158/1078-0432.CCR-12-0715

NATURE MEDICINE 2023: The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Luke J, Patel M, Blumenschein G, Hamilton E, Chmielowski B, Ulahannan S, Connolly R, Santa-Maria C, Wang J, Bahadur S, Weickhardt A, Asch A, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler H, Sumrow B, Kaminker P, Chen F, Zhang X, Shah K, Smith D, De Costa A, Li J, Li H, Sun J & Moore P; Nat Med (2023). https://doi.org/10.1038/s41591-023-02593-0

SITC 2020 - A Phase 1 Evaluation of Tebotelimab, a Bispecific PD-1 x LAG-3 DART® Molecule, in Combination with Margetuximab in Patients with Advanced HER2+ Neoplasms
Patel MR, Luke JJ, Hamilton E, Chmielowski B, Blumenschein G, Kindler H, Bahadur S, Santa-Maria CA, Koucheki J, Sun J, Chen F, Zhang X, Muth J, Kaminker P, Moore PA, Sumrow BJ, Ulahannan SV

ASCO 2020 - A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
Jason J. Luke, Manish R. Patel, Erika Hamilton, Girish Mallesara, Andrew Weickhardt, Scott Currence, Linzhi Xu, Sanjeev Kaul, Francine Chen, Paul A. Moore,  Ezio Bonvini, Bradley J. Sumrow, George Blumenschein

SITC 2017 - Preclinical Characterization of MGD013, a PD-1 x LAG-3 Bispecific DART® Molecule
Ross La Motte-Mohs, Kalpana Shah, Jennifer G. Brown, Doug Smith, Sergey Gorlatov, Valentina Ciccarone, James K. Tamura, Hua Li, Jill R. Rillema, Monica Licea, Christine Shoemaker, Leilei He, Farha Vasanwala, Jessica Hill, Arin Whiddon, Massimiliano Pascuccio, Shereen Saini, Francine Z. Chen, Anushka De Costa, Ann Easton, Peter Lung, Jonathan Li, Kurt Stahl, Jeffrey Nordstrom, Scott Koenig, Ezio Bonvini, Syd Johnson and Paul A. Moore

AACR 2016 - MGD013, a Bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) Protein with T-cell Immunomodulatory Activity for Cancer Treatment
Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Sergey Gorlatov, Valentina Ciccarone, James Tamura, Hua Li, Jill Rillema, Monica Licea, Shereen Saini-Lal, Peter Lung, Anushka De Costa, Leilei He, Farha Vasanwala, Wei Chen, Xiao-Tao Yao, Haiquan Li, Thuy Bui, Francine Chen, Jennifer G. Brown, Jeffrey Nordstrom, Scott Koenig, Ezio Bonvini, Syd Johnson, and Paul A. Moore

ASH 2020 - Prophylactic Ruxolitinib for Cytokine Release Syndrome in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
Geoffrey L. Uy, MD; Michael P. Rettig, Stephanie Christ, MS; PhD; Ibrahim Aldoss, MD; Michael Byrne, DO; Harry Erba, MD, PhD; Martha L. Arellano, MD; Matthew C Foster, MD; John E. Godwin, MD; Farhad Ravandi, MD; Peter H. Sayre, MD, PhD; Anjali S. Advani, MD; Matthew J. Wieduwilt, MD, PhD; Ashkan Emadi, MD, PhD; Laura Michaelis, MD; Patrick J. Stiff, MD; Martin Wermke, MD; Norbert Vey, MD, PhD; Patrice Chevalier, MD PhD; Emmanuel Gyan, MD, PhD; Christian Recher, MD PhD; Fabio Ciceri, MD; Matteo Giovanni Carrabba, MD; Stefania Paolini, MD; Antonio Curti, MD, PhD; GerwinA Huls, MD, PhD; Mojca Jongen-Lavrencic, MD, PhD; John Muth, MS; Teia Curtis, BA; Marybeth Collins, BS; Erin Fehr, BS; Kuo Guo, MSc; Jian Zhao, PhD; Kathy Tran, BS; Patrick Kaminker, PhD; Priyanka Patel, Pharm D.; Ouiam Bakkacha, MD; Kenneth Jacobs, MD; Maya Kostova, PhD; Jennifer Seiler, PhD, RAC; Bob Löwenberg, MD, PhD; Sergio Rutella, MD, PhD, FRCPath; Roland B. Walter, MD, PhD, MS; Ezio Bonvini, MD; Jan K Davidson-Moncada, MD, PhD; John F. DiPersio, MD, PhD

ASH 2020 - Microenvironmental Immune Senescence and Exhaustion in AML Associate with Response to Flotetuzumab
Jayakumar Vadakekolathu, Tung-On Yau, Sarah E. Church, Michael P. Rettig, Ibrahim Aldoss, Geoffrey L. Uy, Norbert Vey, Ashkan Emadi, Peter H. Sayre, Roland B. Walter, Matthew C. Foster, Martha L. Arellano, John E. Godwin, Matthew J. Wieduwilt, Michael Byrne, Laura Michaelis, Patrick J. Stiff, Matteo G. Carrabba, Patrice Chevallier, Emmanuel Gyan, Christian Recher, Anjali S. Advani, Martin Wermke, Harry P. Erba, Fabio Ciceri, Gerwin A. Huls, Mojca Jongen-Lavrencic, Max S. Topp, Farhad Ravandi, Stefania Paolini, Antonio Curti, John Muth, Patrick Kaminker, Bob Löwenberg, Ezio Bonvini, Ivana Gojo, Leo Luznik, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella

ASH 2020 - Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in AML
Jayakumar Vadakekolathu, Tung On Yau, Heidi Altmann, Sarah E. Church, Hanna Knaus, Mark D. Minden, Jan Davidson-Moncada, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik, Sergio Rutella

ASH 2020 - TP53 Abnormalities - Response to Flotetuzumab in AML
Catherine Lai, Jayakumar Vadakekolathu, Stephen Reeder, Sarah E. Church, Carmen Ballesteros-Merino, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano,Geoffrey Uy, FarhadRavandi, Matthew Foster, Emmanuel Gyan, Patrick Stiff, Norbert Vey, Ashkan Emadi, Matteo Carrabba, Peter Sayre, Roland Walter, Kathy Tran, Erin Timmeny, Michael Rettig, Patrick Kaminker, John Muth, Kuo Guo, Tung On Yau, Peter J.M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella

ASH 2020 - Flotetuzumab Upregulates MHC Class II Expression on AML
Joseph Rimando, MD; Michael Rettig, PhD; Matt Christopher, MD, PhD; Miriam Kim, MD; John Muth, MS; Jan K. Davidson‐Moncada, MD, PhD; John DiPersio, MD, PhD

ASH 2020 - Flotetuzumab as Salvage Therapy for PIF and ER AML
Ibrahim Aldoss, MD; Geoffrey L. Uy, MD; Norbert Vey, MD, PhD; Ashkan Emadi, MD, PhD; Peter H. Sayre, MD, PhD; Roland B. Walter, MD, PhD, MS; Matthew C Foster, MD; Martha L. Arellano, MD; John E. Godwin, MD; Matthew J. Wieduwilt, MD, PhD; Michael Byrne, DO; Laura Michaelis, MD; Patrick J. Stiff, MD; Matteo Giovanni Carrabba, MD; Patrice Chevallier, MD, PhD; Emmanuel Gyan, MD, PhD; Christian Recher MD, PhD; Anjali S. Advani, MD; Martin Wermke, MD; Harry Erba, MD, PhD; Fabio Ciceri, MD; GerwinA Huls, MD, PhD; MojcaJongen-Lavrencic, MD, PhD;Max S. Topp, MD, PhD; FarhadRavandi, MD; Stefania Paolini, MD; Antonio Curti, MD, PhD; Michael P. Rettig, PhD; John Muth, MS; TeiaCurtis, BA; Marybeth Collins, BS; Erin Fehr, BS; Kuo Guo, MSc; Jian Zhao, PhD; Kathy Tran, BS; Patrick Kaminker, PhD; Priyanka Patel, Pharm D.; OuiamBakkacha, MD; Kenneth Jacobs, MD; Maya Kostova, PhD; Jennifer Seiler, PhD, RAC; Bob Löwenberg, MD, PhD; Sergio Rutella, MD, PhD, FRCPath; Ezio Bonvini, MD; Jan K Davidson-Moncada, MD, PhD; John F. DiPersio, MD, PhD

BLOOD ADVANCES 2020 - TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in AMLML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J. M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella. Blood Advances (2020) 4 (20): 5011–5024.

BLOOD 2020 - Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, Peter H Sayre, Matthew J Wieduwilt, Anjali S. Advani, John E Godwin, Martha L. Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura C. Michaelis, Max S Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick Stiff, Kristen Pettit, Bob Löwenberg, Sarah Church, Erica Katherine Anderson, Jayakumar Vadakekolathu, Marianne T Santaguida, Michael P Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, MD, Kathy Tran, Patrick Kaminker, Maya Kostova, Dr, Ezio Bonvini, Roland B Walter, Jan Kenneth Davidson-Moncada, Sergio Rutella, John F DiPersio; doi.org/10.1182/blood.2020007732; BLOOD, September 2020.

AACR 2020 - TP53 Abnormalities Correlate with Immune Infiltration and are Associated with Response to Flotetuzumab, an Investigational Immunotherapy, in Acute Myeloid Leukemia
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder,Sarah E. Church, Tressa Hood, John Muth, Heidi Altmann, Marilena Ciciarello,AntonioCurti, PeterJ.M. Valk, BobLöwenberg, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, and Sergio Rutella

ASH 2019 - A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei, Chun Yew Fong, Pau Montesinos, Maria Calbacho, Jordi Sierra, Jaime Perez De Oteyza, Jacob M. Rowe, Ofir Wolach, Yishai Ofran, Yakir Moshe, Jichao Sun, Jan Baughman, Eileen McNulty, Ezio Bonvini, Jon M. Wigginton and Jan K Davidson-Moncada

ASH 2019 - Flotetuzumab: an Investigational CD123xCD3 Bispecific DART® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies is Associated with Response to Treatment in Primary Refractory AML Patients
John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn M. Jensen, Tarsem Moudgil, Carlo B. Bifulco, Sarah E. Church, Thomas Smith, Michael Bailey, James Gowen-MacDonald, Sergio Rutella, Jon M. Wigginton, John Muth, Jan Davidson-Moncada, Bernard A. Fox

ASH 2019 - Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Mark D. Minden, Tressa Hood, Sarah E. Church, Stephen Reeder, Heidi Altmann, Amy H. Sullivan, Elena J. Viboch, Tasleema Patel, Narmin Ibrahimova, Sarah E. Warren, Andrea Arruda, Yan Liang, Marc Schmitz, Alessandra Cesano, Peter J.M. Valk, Bob Löwenberg, A. Graham Pockley, Martin Bornhäuser, Sarah K. Tasian, Michael P. Rettig, Jan Davidson-Moncada, John F. DiPersio

ASH 2019 - Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART® Protein, in Salvage Therapy for Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia Patients
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C Foster, David A Sallman, Kendra L. Sweet, David A. Rizzieri, Peter H. Sayre, Anjali S. Advani, Ashkan Emadi, Matthew J. Wieduwilt, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Tamara Moyo, Sarah E. Church, Michael P. Rettig, Martha L. Arellano, John E. Godwin, Bob Löwenberg, GerwinHuls, FarhadRavandi, John Muth, Kathy Tran, Ouiam Bakkacha, Kenneth Jacobs, MojcaJongen-Lavrencic, Erin Timmeny, Max S. Topp, Stefania Paolini, KuoGuo, Teia Curtis, Jian Zhao, Jayakumar Vadakekolathu, Jon M. Wigginton, Ezio Bonvini, Sergio Rutella, M Roland B. Walter, Jan K Davidson-Moncada, and John F. DiPersi

BLOOD 2016 - Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L and DiPersio JF Blood 2016 127:122-131

ASH 2018 - Biomarkers and Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DART® Molecule for T-cell Redirected Therapy
Kenneth Jacobs, Cedric Viero, John Godwin, Jan Baughman, Jichao Sun, Kang Ying, John Muth, Shengyan Hong, Norbert Vey, Kendra L. Sweet, Geoffrey L. Uy, Farhad Ravandi, Matthew C Foster, David A. Rizzieri,  Martha L. Arellano, Michael P. Rettig, Max S. Topp, Gerwin Huls, Helene Lelièvre, Stefania Paolini, Fabio Ciceri, Matteo Giovanni Carrabba, Bob Löwenberg, John F. DiPersio, Jon Wigginton1 and Jan K. Davidson-Moncada

ASH 2018 - Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 ×CD3 Bispecific DART® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sergio Rutella, Sarah E. Church, Jayakumar Vadakekolathu, Elena Viboch, Amy H. Sullivan, Tressa Hood, Sarah E. Warren, Alessandra Cesano, Ross La Motte-Mohs, John Muth, Helene Lelièvre, Bob Löwenberg, John F. DiPersio and Jan K. Davidson-Moncada

ASH 2018 - Bone Marrow T Cell Changes by Multiplex IHC After Treatment with Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in a Primary Refractory t-AML Patient
John E. Godwin, Carmen Ballesteros-Merino, Carlo B. Bifulco, Helene Lelièvre, Jon M. Wigginton, Jan Davidson-Moncada, Bernard A. Fox

ASH 2018 - Phase 1 Cohort Expansion of Flotetuzumab, a CD123 x CD3 Bispecific DART® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Geoffrey L. Uy, MD, Michael P Rettig, PhD, Norbert Vey, MD, John Godwin, MD, Matthew Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, MD, Gerwin Huls, MD, PhD, Mojca Jongen-Lavrencic, MD, PhD, Giovanni Martinelli, MD, Stefania Paolini, MD, PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra Sweet, MD, Farhad Ravandi, MBBS, Sarah E Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD, PhD, FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La MotteMohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD, PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Löwenberg, MD, PhD, Jan K DavidsonMoncada, MD, PhD and John F DiPersio, MD, PhD

Keystone 2018 - Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Ling Huang, Ross La-Motte Mohs, Chia-Ying Kao Lam, Liqin Liu, Thomas Kaufman, Gurunadh Chichili, Ralph Alderson, Kurt Stahl, Jennifer G. Brown, Paul Moore, Syd Johnson and Ezio Bonvini

ASH 2017 - Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Michael P Rettig, John Godwin, Norbert Vey, Bernard Fox, Carmen Ballesteros-Merino, Carlo B Bifulco, Daner Li, Daniel Primo, Joan Ballesteros, Jichao Sun, Helene Lelièvre, Jan Baughman, Ross La Motte-Mohs, John Muth, Paul Moore, Ezio Bonvini,  Jon Wigginton, John F DiPersio and Jan Davidson-Moncada

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Chichili G, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore P, Johnson S, Bonvini E. Sci Transl Med 27 May 2015; Vol. 7, Issue 289, 289ra82.

SABCS 2021 - Phase 3 SOPHIA Study of Margetuximab + Chemotherapy Versus Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies: Final Overall Survival Analysis
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William R. Gwin III, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Emily Ashley, Shengyan Hong, Minori Rosales, William J. Gradishar; on behalf of the SOPHIA Study Group

ESMO 2021 - Margetuximab With Retifanlimab in HER2+, PD-L1+ First-Line Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A
Catenacci D, Park H, Shim BY, Kim ST, Oh D-Y, Spira A, Ulahannan S, Avery E, Boland P, Chao J, Chung HC, Gardner F, Klempner S, Lee K-W, Oh SC, Peguero J, Sonbol M, Yoon HH, Shen L, Moehler M, Sun J, Rosales M, Kang Y-K

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
A Phase 3 Randomized Clinical Trial
Hope S. Rugo, MD; Seock-Ah Im, MD, PhD; Fatima Cardoso, MD; Javier Cortés, MD, PhD; Giuseppe Curigliano, MD, PhD; Antonino Musolino, MD, PhD, MSc; Mark D. Pegram, MD; Gail S. Wright, MD; Cristina Saura, MD, PhD; Santiago Escrivá-de-Romaní, MD; Michelino De Laurentiis, MD, PhD; Christelle Levy, MD; Ursa Brown-Glaberman, MD; Jean-Marc Ferrero, MD; Maaike de Boer, MD, PhD; Sung-Bae Kim, MD, PhD; Katarína Petráková, MD, PhD; Denise A. Yardley, MD; Orit Freedman, MD, MSc; Erik H. Jakobsen, MD; Bella Kaufman, MD; Rinat Yerushalmi, MD; Peter A. Fasching, MD; Jeffrey L. Nordstrom, PhD; Ezio Bonvini, MD; Scott Koenig, MD, PhD; Sutton Edlich, MS, PA; Shengyan Hong, PhD; Edwin P. Rock, MD, PhD; William J. Gradishar, MD; for the SOPHIA Study Group

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Daniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E Uronis, Keun-Wook Lee, Matthew C H Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster*, Sang Cheul Oh, Yeul Hong Kim, Kristen A Marrone, Ronan J Kelly, Rosalyn A Juergens, Jong Gwang Kim, Johanna C Bendell, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim†, A Craig Lockhart‡, Keith L Knutson, Jennifer Yen, Aleksandra Franovic, Jeffrey L Nordstrom, Daner Li, Jon Wigginton, Jan K Davidson-Moncada, Minori Koshiji Rosales, Yung-Jue Bang, on behalf of the CP-MGAH22-5 Study Group

ASCO 2020 - SOPHIA Analysis by Chemotherapy (Ctx) Choice: A Phase 3 (P3) Study of Margetuximab (M) + Ctx vs Trastuzumab (T) + Ctx in Patients (pts) with Pretreated HER2+ Metastatic (met) Breast Cancer (MBC)
Santiago Escriva-de-Romani, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, William J. Gradishar, Mark D. Pegram, Gail S. Wright, Christelle Levy, Michelino De Laurentiis,  Jean-Marc Ferrero, Shakeela W. Bahadur, Sung-Bae Kim, Katarína Petráková, David A. Riseberg, Denise Yardley, Sutton Edlich, Shengyan Hong, Edwin Rock, Hope S. Rugo, on behalf of the SOPHIA Study Group

SABCS 2019 - Phase 3 SOPHIA Study of Margetuximab + Chemotherapy vs Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies: Infusion Time Substudy Results
William J. Gradishar, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Rossana Berardi, Michelino De Laurentiis, Shakeela W. Bahadur, Young-Hyuck Im, Cynthia Lynch, Yelena Novik, Sutton Edlich, Edwin Rock, Shengyan Hong, and Hope S. Rugo, on behalf of the SOPHIA Study Group

SABCS 2019 - Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Thomas Bachelot, Gail S. Wright, Michelino De Laurentiis, Peter A. Kaufman, Timothy Pluard, Francesco Ricci, Lupe G. Salazar, Denise A. Yardley, Sutton Edlich, Shengyan Hong, Edwin Rock, William J. Gradishar, on behalf of the SOPHIA Study Group

ESMO 2019 - Determinants of Response of HER2+ Gastric Cancer vs Gastroesophageal Junction Adenocarcinoma to Margetuximab plus Pembrolizumab post Trastuzumab
H. Park, H.E. Uronis, Y-K. Kang, M. Ng, P.C. Enzinger, K.W. Lee, S. Rutella, S. Church, J. Nordstrom, Y. Yang, P. Moore, D. Li, K. Knutson, C. Erskine, T. Wu, J. Yen, A. Franovic, J. Muth, M. Rosales, J. Vadakekolathu, J. Davidson-Moncada, Y.J. Bang, D.V.T. Catenacci

ESMO 2019 - Evaluation of Tumor Microenvironment Identifies Immune Correlates of Response to Combination Immunotherapy with Margetuximab (M) and Pembrolizumab (P) in HER2+ Gastroesophageal Adenocarcinoma (GEA)
S. Rutella, S.E. Church, J. Vadakekolathu, S. Reeder, A. Sullivan, S. Warren, J. Baughman, J. Muth, H. Park, H. Uronis, Y-K. Kang, M. Ng, P. Enzinger, K.W. Lee, K. Huber, A. Wynter-Horton, D. Li, Y-J. Bang, J. Davidson-Moncada, D. Catenacci

ESMO 2019 - Margetuximab plus Pembrolizumab for Treatment of Patients with HER2-Positive Gastroesophageal Adenocarcinoma (GEA) Post-Trastuzumab: Survival Analysis
D.V.T. Catenacci, H. Park, H.E. Uronis, Y.-K. Kang, M. Ng, P.C. Enzinger, K.-W. Lee, K.H. Lim, P.J. Gold, J. Lacy, S.H. Park, K. Huber, A. Wynter-Horton, J. Nordstrom, Y. Yang, P. Moore, D. Li, T. Wu, J. Wigginton, J. Baughman, M. Rosales, J. Davidson-Moncada, Y. J. Bang

ASCO GI 2019 - Antitumor Activity of Margetuximab plus Pembrolizumab in Patients with Advanced HER2+ (IHC3+) Gastric Carcinoma
Daniel V.T. Catenacci, Haeseong Park, Hope Elizabeth Uronis, Yoon-Koo Kang, Matthew C.H. Ng, Philip Jordan Gold, Peter C. Enzinger, Keun Wook Lee, Jill Lacy, Se Hoon Park, Jennifer Yen, Justin Odegaard, Aleksandra Franovic, Sarah Church, Anushka DeCosta, Jan E. Baughman, Aisha Wynter-Horton, Francine Chen, Jeff Nordstrom , Paul A. Moore, Tony Wu, Jan Kenneth Davidson-Moncada, Yung-Jue Bang

ASCO 2019 - SOPHIA Primary PFS Analysis: A Phase 3 Study of Margetuximab + Chemotherapy vs Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies
Hope S. Rugo, Seock-Ah Im, Gail S. Wright, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Javier Cortes, Shakeela W. Bahadur, Barbara B. Haley, Raul H. Oyola, David A. Riseberg, Antonino Musolino, Fatima Cardoso, Giuseppe Curigliano, Peter A. Kaufman, Mark D. Pegram, Sutton Edlich, Shengyan Hong, Edwin Rock, William J. Gradishar, on behalf of the SOPHIA Study Group

ASCO 2019 - High Frequency of HER2-specific Immunity Observed in Patients (pts) with HER2+ Cancers Treated with Margetuximab (M), An Fc-enhanced Anti-HER2 Monoclonal Antibody (mAb)
Jeffrey L. Nordstrom, John Muth, Courtney L. Erskine, Catherine Sanders, Erik C. Yusko, Ryan Emerson, Min-Jung Lee, Sunmin Lee, Jane Trepel, Yung-Jue Bang, Seock-Ah Im, Giuseppe Giaccone, Todd Michael Bauer, Howard A. Burris III, Jan E. Baughman, Edwin P. Rock, Paul A. Moore, Ezio Bonvini, KL Knutson

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA. Ann Oncol. 2017 Apr 1;28(4):855-861

AACR 2019 - Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro
Liqin Liu, Yinhua Yang, Robert Burns, Jonathan Li, Haiquan Li, Sergey Gorlatov, Paul Moore, Jeffrey Nordstrom

SABCS 2018 - Long-Term Responders to Single-Agent Margetuximab, an Fc-Modified Anti-HER2 Monoclonal Antibody, in Metastatic HER2+ Breast Cancer Patients with Prior Anti-HER2 Therapy
S. A. Im, Y. J. Bang, D. Y. Oh, G. Giaccone, T. M. Bauer, J. L. Nordstrom, H. Li, P. A. Moore, S. Hong, J. E. Baughman, E. Rock, H. A. Burris

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties
Nordstrom J, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S. Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart S, Moore P, Johnson S, Bonvini E. Breast Cancer Research, 2011 November 30;13:R123.

ESMO 2020 - POD1UM 202: Phase 2 Study of Retifanlimab in Patients With Squamous Carcinoma of the Anal Canal Who Progressed Following Platinum Based Chemotherapy
Sheela Rao, Jaume Capdevila, Duncan Gilbert, Stefano Kim, Laetitia Dahan, Talal Kayyal, Marwan Fakih, Anne Demols, Lars H. Jensen, Karen Lise Spindler, Dirk Arnold, Stefano Tamberi, Marianne G. Guren, Mark Cornfeld, Mark Jones, Chuan Tian, Melissa Catlett, Jean Philippe Spano

SITC 2019 - A Phase 1 Study of INCMGA00012, a PD-1 Inhibitor, in Patients With Advanced Solid Tumors: Preliminary Results for Patients With Advanced Cervical Cancer (POD1UM-101)
Janice M. Mehnert, Luis Paz-Ares, Joanna Pikiel, Udai Banerji, Anna Kryzhanivska, Nehal Lakhani, Sebastian Ochsenreiter, Tobias Arkenau, Deanna Kornacki, Chuan Tian, Thomas Condamine, Nawel Bourayou, Itziar Gardeazabal González

SITC 2019 - Preliminary Results of a Phase 2 Study of INCMGA00012 in Patients With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Sheela Rao, Jaume Capdevila, Duncan Gilbert, Stefano Kim, Laetitia Dahan, Talal Kayyal, Marwan Fakih, Anne Demols, Mark Cornfeld, Chuan Tian, Melissa Catlett, Jean-Philippe Spano

AACR 2019 - Pharmacodynamic Correlates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody
Thomas Condamine, Sherry Owens, Pat Feldman, Ross La Motte-Mohs, John Muth, Bradley Sumrow, Paul Moore, Robert Newton

AACR 2019 - Assessment of Flat Dosing Strategy for INCMGA00012 in Patients With Advanced Tumors
Xuejun Chen, Phil Wang, Sanjeev Kaul, Bradley Sumrow, Swamy Yeleswaram

SITC 2018 - First-in-Human Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors: Interim Results of the Cohort Expansion Phase
Janice Mehnert, Anthony Joshua, Nehal Lakhani, Udai Banerji, Drew Rasco, Iwona Lugowska, Monica Tomaszewska-Kiecana, Elena Garralda, Deanna Kornacki, Bradley Sumrow, Nawel Bourayou, Chuan Tian, John Powderly

SITC 2017 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in Patients with Advanced Solid Tumors
Nehal Lakhani, Janice M. Mehnert, Drew Rasco, Michael Gordon, Joanna Lohr, Sharad Sharma, Hua Li, Ross LaMotte-Mohs, Paul Moore, Jichao Sun, Pepi Pencheva, Brad Sumrow, Jon Wigginton, John Powderly

SITC 2017 - Preclinical Characterization of MGA012, A Novel Clinical-stage PD-1 Monoclonal Antibody
Ross La Motte-Mohs, Kalpana Shah, Jennifer G. Brown, Ralph F. Alderson, Doug Smith, Sergey Gorlatov, Valentina Ciccarone, James K. Tamura, Hua Li, Jill R. Rillema, Monica Licea, Leilei He, Farha Vasanwala, Jessica Hill, Christina Wolff, Massimiliano Pascuccio, Francine Z. Chen, Yan Chen, Anushka De Costa, Ann Easton, Alexey Berezhnoy, Jonathan Li, Jeffrey Nordstrom, Scott Koenig, Ezio Bonvini, Syd Johnson and Paul A. Moore

ASH 2021 - Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific DART® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia
Ralph F. Alderson, PhD, Ling Huang, Xiaoyu Zhang, Haiquan Li, Thomas Kaufman, Gundo Diedrich, PhD, Paul Moore, PhD and Ezio Bonvini, MD

MOLECULAR CANCER THERAPEUTICS - Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
Juniper A. Scribner, Stuart W. Hicks, Kerstin W. Sinkevicius, Nicholas C. Yoder, Gundo Diedrich, Jennifer G. Brown, Jacquelynn Lucas, Megan E. Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher Espelin, Marian Themeles, Francine Z. Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A. McEachem, Scott Koenig, Eric H. Westin, Paul A. Moore, Thomas Chittenden, Richard J. Gregory, Ezio Bonvini, and Deryk Loo; DOI: 10.1158/1535-7163.MCT-21-0915; Molecular Cancer Therapeutics, July 2022.

AACR 2019 - IMGC936, a First in-class ADAM9-targeting Antibody-drug Conjugate, Demonstrates Promising Anti-tumor Activity
Stuart W. Hicks, Deryk Loo, Kerstin Sinkevicius, Juniper A. Scribner, Bhaswati Barat, Nicholas C. Yoder, Christopher Espelin, Francine Z. Chen, Marian Themeles, Jacquelynn Lucas, Jennifer G. Brown, Bahar Matin, Megan E. Fuller, Jenny Lee, Paulin L. Salomon, Juliet Costoplus, Sadiqa Yancey, Gundo Diedrich, Sergey Gorlatov, Thomas Son, Christina Wolff, Michael Chiechi, Pam Li, Michael Spliedt, Valentina Ciccarone, Jeff Hooley, Nadia Gantt, James Tamura, Kerry A. Donahue, Paul A. Moore, Syd Johnson, Thomas Chittenden, Richard Gregory, Ezio Bonvini

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E. Advances in Enzyme Regulation 2007 December 3.

AACR II 2020 - Investigational CD25 x CTLA-4 Bispecific DART® Molecule for Depletion of Tumor Infiltrating Tregs via an Enhanced Fc-dependent Effector Mechanism
Berezhnoy A., Shah K., Liu D., Hao S., Rillema J., Fieger C., Smith D., Lung P., De Costa A., Chen F., Tamura J., Bonvini E., Diedrich G., Moore P.A.

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O’Sullivan C, Cummins E, Lambert M, Sheehan AD, Ma W, Gatto S, Kerns K, Lam K, D’Antona AM, Zhu L, Brady WA, Benard S, King A, He T, Racie L, Arai M, Barrett D, Stochaj W, LaVallie ER, Apgar JR, Svenson K, Mosyak L, Yang Y, Chichili GR, Liu L, Li H, Burke S, Johnson S, Alderson R, Finlay WJJ, Lin L, Olland S, Somers W, Bonvini E, Gerber H-P, May C, Moore PA, Tchistiakova L and Bloom L Antibodies 2016; 5(1): 6

Keystone 2018 - Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing
Huang L, La-Motte Mohs R, Kao Lam C-Y, Liu L, Kaufman T, Chichili G, Alderson R, Stahl K, Brown JG, Moore P, Johnson S and Bonvini E

Effector cell recruitment with novel fv-based dual-affinity retargeting protein leads to potent tumor cytolysis and in vivo b-cell depletion
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. J Mol Biol, 2010 Apr 9;399(3):436-49.

Application of dual-affinity re-targeting (DART) molecules to achieve optimal redirected t-cell killing of b-cell lymphoma
Paul A. Moore, Wenjun Zhang, G. Jonah Rainey, Steve Burke, Hua Li, Ling Huang, Sergey Gorlatov, Maria Concetta Veri, Sudeppta Aggarwal, Yinhua Yang, Kaplana Shah, Linda Jin, Sunan Zhang, Leilei He, Tengfei Zhang, Valentina Ciccarone, Scott Koenig, Ezio Bonvini and Syd Johnson; Blood, 2011; 117(17):4542-4551.

AACR 2019 - Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ Molecules
Liqin Liu, Ling Huang, Vatana Long, Yinhua Yang, Robert Burns, Jonathan Li, Jennifer DiChiara, Qihong Xu, Chia-Ying K. Lam, Jim Tamura, Valentina Ciccarone, Syd Johnson, Ezio Bonvini and Paul A. Moore

AACR 2019 - Selection of a Bispecific Trivalent HER2 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation
Liqin Liu, Chia-Ying K. Lam, Ralph Alderson, Vatana Long, Yinhua Yang, Robert Burns, Lusiana Widjaja, Jonathan Li, Christina Wolff, Valentina Ciccarone, James Tamura, Gundo Diedrich, Ezio Bonvini, Syd Johnson, Paul A. Moore